Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Victoza’s Non-Cardio Safety May Dominate At FDA Panel Review

Executive Summary

US FDA does not raise any major concerns about study’s design or results to support cardiovascular risk reduction claim for Novo Nordisk’s GLP-1 agonist liraglutide ahead of advisory committee, but agency gives close scrutiny to non-CV safety events of interest.


Related Content

Novo Nordisk's Victoza Adds CV Benefit Claim, But Not For Primary Prevention
Novo’s Victoza CV Benefit Claim Could Be Narrowed With FDA Panel Vote
Recent And Upcoming FDA Advisory Committee Meetings
FDA Conflict Of Interest Waiver On Victoza Is Textbook Example For Supporters, Foes
Jardiance's Cardiovascular Benefit Claim Bodes Well For Other Products Too
Can A Safety Study Support A Superiority Claim? Barely, FDA Advisors Say
Jardiance Mortality Claim Narrowly Endorsed By FDA Advisory Committee
Jardiance's CV Benefit: Can A Single Study Carry The Day At FDA?
Novo Will Go After MACE Indication For Victoza Based On LEADER
Novo Nordisk’s Liraglutide Gets Panel Nod For Weight Management


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts